The content on this site is intended for healthcare professionals only
Dr Komal Jhaveri speaks to ecancer about the latest updates from the SUMMIT trial. This trial investigates neratinib + fulvestrant + trastuzumab for hormone receptor-positive, HER2-mutant metastatic breast cancer and neratinib + trastuzumab for triple-negative disease.
Dr Jahveri talks about the background and methodology of the trial before going on to report the results.
She says that the combination of neratinib + fulvestrant + trastuzumab demonstrated encouraging clinical activity in heavily pre-treated HER2-mutant, HR+, HER2-non-amplified mBC, including patients who had previously received either fulvestrant and/or CDK4/6 inhibitor-based therapies.
While the rate of grade 3 diarrhoea was higher than that observed with single-agent neratinib in SUMMIT, this was manageable through loperamide prophylaxis, and no patients discontinued study treatment due to diarrhoea.
She concludes by mentioning how these results can impact the future treatment of breast cancer.
Sacituzumab govitecan plus pembrolizumab improves PFS across biomarker subgroups in metastatic triple-negative breast cancer
Gene expression test guided therapy in ER+/HER2- early breast cancer allows safe chemotherapy omission
Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients unable to receive PD-(L)1 inhibitors
Burden and trends of breast cancer worldwide: Opportunities for prevention?
HER3-DXd demonstrates similar efficacy compared to multi-agent chemotherapy in high-risk HR-positive/HER2-negative eBC
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer
Durable responses in aRCC, how do we optimise treatment?
Hormonal receptor positive breast cancer adjuvant and metastatic indications
